Anti-PD1

Phase 3Small molecule

Pfizer

Anti-PD1 is one of 64 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

MelanomaActive, not recruiting

Nasopharyngeal CarcinomaPreclinical

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Cotellic

Roche

Phase 3

21 2

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

27 3

Rhuph20

Bristol-Myers Squibb

Phase 3

1 4

Pegylated Interferon-Alpha-2a

AstraZeneca

Phase 3

1 5

Single Dose of

Boehringer Ingelheim

Phase 3

1 6

Tumor Necrosis Factor

NNational Cancer Institute (NCI)

Phase 3

1 7

Interferon-Alpha-2a

Roche

Phase 3

1 8

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

39 9

Anti-PD1

Pfizer

Phase 3

1 10

BCD-217

BBiocad

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Melanoma

NCT05751928

Clinical

Trials by Indication[1]

Gastrointestinal Tumors1 trial

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Terminated· Pfizer logo

Pfizer·Phase 1·NCT04171141·79 enrolled

Nasopharyngeal Carcinoma1 trial

Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma

Completed·—·N/A·NCT06676293·8 enrolled

Unresectable Cancer1 trial

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

Terminated·IImmodulon Therapeutics Ltd·Phase 1/2·NCT03009058·2 enrolled

Melanoma1 trial

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

Active, not recruiting·BBiocad·Phase 3·NCT05751928·411 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Anti-PD1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-PD1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-PD1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Anti-PD1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Gastrointestinal Tumors1 trial

Nasopharyngeal Carcinoma1 trial

Unresectable Cancer1 trial

Melanoma1 trial

References

Drug Info

Quick Facts

Related News